Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14072386 | 0.71 | ALDH1A1 (0.31) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL2609999 | 0.68 | ALDH1A1 (0.36) | MEN1KMT2AHRH3ALDH1A1HPGD | |
| SCHEMBL14072353 | 0.68 | ALDH1A1 (0.33) | NPSR1MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL14072401 | 0.67 | TMEM97 (0.40) | MEN1KMT2AHRH3ALDH1A1HPGD | |
| SCHEMBL19910555 | 0.65 | NR1H3 (0.34) | HRH3ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL22400019 | 0.65 | BMPR1B (0.47) | MEN1POLBKMT2AHRH3ALDH1A1 | |
| SCHEMBL23594623 | 0.62 | HRH3 (0.40) | HRH3 | |
| SCHEMBL24478509 | 0.62 | HRH3 (0.46) | MEN1KMT2AHRH3ALDH1A1 | |
| SCHEMBL19910558 | 0.61 | CYP3A4 (0.39) | HRH3ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL14072402 | 0.61 | NPC1 (0.44) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221094-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221093-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP12, MMP13, MMP25 | NPSR1 1482/4885MEN1 1893/4885POLB 2906/4885 |
| US-20080221094-A1 | Metalloprotease inhibitors containing a squaramide moiety | MMP13, MMP14, MMP11 | NPSR1 1508/4885MEN1 2850/4885POLB 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.